Back to Search
Start Over
Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors
- Publication Year :
- 2017
-
Abstract
- Neuroendocrine tumors (NETs) represent a large and heterogeneous group of malignancies with various biological and clinical characteristics, depending on the site of origin and the grade of tumor proliferation. In NETs, as in other cancer types, molecularly targeted therapies have radically changed the therapeutic landscape. Recently two targeted agents, the mammalian target of rapamycin inhibitor everolimus and the tyrosine kinase inhibitor sunitinib, have both demonstrated significantly prolonged progression free survival in patients with advanced pancreatic NETs. Despite these important therapeutic developments, there are still significant limitations to the use of these agents due to the lack of accurate biomarkers for predicting tumor response and efficacy of therapy. In this review, we provide an overview of the current clinical data for the evaluation of predictive factors of response to/efficacy of everolimus and sunitinib in advanced pancreatic NETs. Surrogate indicators discussed include circulating and tissue markers, as well as non-invasive imaging techniques.
- Subjects :
- 0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Indoles
medicine.drug_class
Antineoplastic Agents
Neuroendocrine tumors
Pharmacology
Tumor response
Tyrosine-kinase inhibitor
03 medical and health sciences
0302 clinical medicine
Tissue markers
Internal medicine
medicine
Sunitinib
Humans
Pharmacology (medical)
Pyrroles
Progression-free survival
Everolimus
Molecular Targeted Therapy
business.industry
Cancer
medicine.disease
Pancreatic Neoplasms
Neuroendocrine Tumors
030104 developmental biology
030220 oncology & carcinogenesis
business
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....72ed297065c32d9f164a5b9db5174790